Orly Leiva: Rethinking JAK Inhibitor Cardiovascular Safety in MPNs
Orly Leiva, Cardio-Oncology and Pulmonary Hypertension Cardiologist, Assistant Professor at University of Kentucky College of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: CardioOncology, adding:
“Excited to share out new publication on the impact of JAK Inhibitors on cardiovascular outcomes in hematologic malignancies, particularly MPNs!
In this JACC Cardio-Oncology primer, we looked at the literature on cardiovascular risk with JAK inhibitors.
On the basis of the ORAL Surveillance trial, which demonstrated increased cardiovascular risk in rheumatoid arthritis with JAK Inhibitor vs TNF inhibitors, the FDA has placed a black box warning on all JAK inhibitors.
However, recent data from our group and others suggest that the impact of JAK inhibition is more nuanced.
Among patients with MPNs, for which JAK inhibitors are sometimes indicated in, suggest that there may be a reduced risk of thrombosis and HF events with JAK inhibition.
The discordance between the literature in RA and other autoimmune diseases and MPNs may be due to underlying disease pathophysiology, specific JAK-STAT types targeted and patient population.
More work needs to be done!
Thanks to Gabriela Hobbs, Michelle Bloom, Angie Seo for their help in this paper and for Michael Garshick for the invitation to help write this important work.
Always fun to mentor NYU Grossman School of Medicine medical students and University of Kentucky College of Medicine cardiology fellows in writing this as well!”
Title: Cardiovascular Considerations of JAK Inhibitors in Patients With Hematologic Malignancies: JACC CardioOncology Primer
Authors: Orly Leiva, Monica Ferrante, Sydney Lupo, Angie E. Seo, Gabriela Hobbs, Michelle Bloom, Michael Garshick
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience